Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
TIPPS: Thrombophilia in Pregnancy Prophylaxis Study
NCT00967382 · View on ClinicalTrials.gov ↗
Study Summary
The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent thrombosis in the leg veins, pulmonary arteries and placental vessels, thereby reducing the risk of deep vein thrombosis, pulmonary embolism (PE), intrauterine growth restriction (IUGR), preeclampsia, miscarriage and stillbirth?
Conditions Studied
Interventions
- DRUG dalteparin sodium
Study Locations (12)
Ontario
- Hamilton Health Sciences Centre — Hamilton
- The Ottawa Hospital, Civic Campus — Ottawa
- Mount Sinai Hospital — Toronto
- Women's College Health Sciences Centre — Toronto
Quebec
- SMBD Jewish General Hospital — Montreal
- St Mary's Hospital Centre — Montreal
- CHA, Hopital Enfant Jesus — Québec
Missouri
- Saint Louis University — St Louis
Utah
- University of Utah Health Sciences Centre — Salt Lake City
Alberta
- Royal Alexandra Hospital — Edmonton
Nova Scotia
- QEII Health Sciences Centre — Halifax
Saskatchewan
- Royal University Hospital — Saskatoon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2000-07 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00967382
The ClinicalTrials.gov registry entry for NCT00967382 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ottawa Hospital Research Institute, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Pregnancy appearing as the primary indexed condition, and to 1 intervention — of which dalteparin sodium is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00967382 reports 12 study locations spanning 7 distinct geographic areas — top geographies include Ontario, Quebec, Missouri. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00967382 about?
NCT00967382 is a clinical study titled "TIPPS: Thrombophilia in Pregnancy Prophylaxis Study". The TIPPS trial seeks to determine the safety and effectiveness of low-molecular-weight heparin (LMWH), an anticoagulant, in preventing placenta mediated pregnancy complications and venous thromboembolism (VTE) in women with thrombophilia. Thus, the principal research question is: can LMWH prevent t...
What is the current status of trial NCT00967382?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2000-07. Estimated completion is 2014-03.
What conditions does trial NCT00967382 study?
This clinical trial studies the following conditions: Pregnancy, Pregnancy Complications, Thrombophilia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00967382?
The interventions under investigation include: dalteparin sodium (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00967382?
This trial is sponsored by Ottawa Hospital Research Institute, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00967382 being conducted?
This trial has 12 study locations across Missouri, Utah, Alberta, Nova Scotia, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.